An update on the recent caselaw on SPCs, the latest news on the study by the Max Planck Institute for Innovation and Competition on the legal aspects of SPCs in Europe, together with (you can’t escape it…) a discussion about the implications for SPCs of a Chequers-inspired Brexit deal (or no deal).
Dr Duncan Curley qualified as a solicitor in 1995. He subsequently became a partner in the intellectual property department of an international law firm. He founded the boutique IP legal practice, Innovate Legal, in 2007. For over 10 years, the firm has acted for multinational and UK-based generic pharmaceutical companies on patent and trademark issues, including freedom to operate, patent clearance and litigation. Duncan is the author of numerous published articles on IP issues and a study entitled “Extending Rewards for Innovative Drug Development”, a Report on Supplementary Protection Certificates that was published by the Intellectual Property Institute in 2007 (so before the recent spate of decisions on SPCs from the Court of Justice of the European Union).